Panagora Asset Management Inc. Sells 5,614 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Other large investors have also made changes to their positions in the company. FinTrust Capital Advisors LLC grew its holdings in shares of NeoGenomics by 27.0% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 1,270 shares of the medical research company’s stock worth $47,000 after acquiring an additional 270 shares during the period. DekaBank Deutsche Girozentrale purchased a new position in shares of NeoGenomics during the 3rd quarter worth approximately $55,000. KBC Group NV purchased a new position in shares of NeoGenomics during the 4th quarter worth approximately $56,000. RWM Asset Management LLC purchased a new position in shares of NeoGenomics during the 4th quarter worth approximately $73,000. Finally, Sowell Financial Services LLC grew its holdings in shares of NeoGenomics by 48.2% during the 4th quarter. Sowell Financial Services LLC now owns 1,918 shares of the medical research company’s stock worth $103,000 after acquiring an additional 624 shares during the period. Institutional investors own 91.06% of the company’s stock.
Shares of NEO stock opened at $44.90 on Wednesday. The business’s fifty day simple moving average is $53.79 and its 200-day simple moving average is $46.37. The company has a market cap of $5.25 billion, a PE ratio of -1,496.17 and a beta of 0.79. The company has a current ratio of 6.54, a quick ratio of 6.22 and a debt-to-equity ratio of 0.25. NeoGenomics, Inc. has a 12-month low of $20.47 and a 12-month high of $61.57.
NeoGenomics (NASDAQ:NEO) last released its earnings results on Wednesday, February 24th. The medical research company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.08. NeoGenomics had a positive return on equity of 0.71% and a negative net margin of 1.16%. The firm had revenue of $126.00 million for the quarter, compared to the consensus estimate of $123.45 million. During the same period in the prior year, the firm earned $0.06 EPS. The firm’s revenue was up 17.8% on a year-over-year basis. On average, equities analysts forecast that NeoGenomics, Inc. will post -0.01 earnings per share for the current year.
A number of research analysts have weighed in on the company. Raymond James reiterated a “market perform” rating on shares of NeoGenomics in a report on Wednesday, March 3rd. SVB Leerink upped their price target on NeoGenomics from $50.00 to $60.00 and gave the stock an “outperform” rating in a research note on Friday, January 8th. BTIG Research initiated coverage on NeoGenomics in a research note on Friday, December 11th. They issued a “buy” rating on the stock. Craig Hallum upped their price objective on NeoGenomics from $50.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 25th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 price objective on shares of NeoGenomics in a research report on Wednesday, March 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. NeoGenomics currently has an average rating of “Buy” and a consensus target price of $48.63.
In other news, VP Jennifer Balliet sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 11th. The shares were sold at an average price of $49.99, for a total transaction of $749,850.00. Following the completion of the sale, the vice president now owns 39,980 shares in the company, valued at approximately $1,998,600.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lawrence Martin Weiss sold 20,200 shares of the firm’s stock in a transaction that occurred on Monday, December 14th. The stock was sold at an average price of $51.06, for a total transaction of $1,031,412.00. Following the sale, the insider now owns 61,717 shares of the company’s stock, valued at approximately $3,151,270.02. The disclosure for this sale can be found here. Over the last three months, insiders have sold 80,200 shares of company stock worth $4,079,012. Corporate insiders own 6.50% of the company’s stock.
About NeoGenomics
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Story: Market Perform
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source